Everolimus is a first‐generation mTOR inhibitor that binds the intercellular receptor FKB12, which then binds and preferentially inactivates the mTOR protein kinase complex 1 (mTORC1) slowing tumor growth, limiting metastatic and local spread, and inhibiting DNA damage repair. Here, MTOR is linked to neoplasm.